


Best Practice Tariff: Tranexamic acid why change

Dr Ian Roberts
Director, Clinical Trials Unit, LSHTM
University of London




TXA reduces surgical bleeding



TXA reduces surgical bleeding


(Ker et al, BJS 2013)

Transfusion



95 trials

Mortality



72 trials

ORIGINAL ARTICLE

Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery

Paul S. Myles, M.P.H., M.D., Julian A. Smith, F.R.A.C.S., Andrew Forbes, Ph.D.,
Brendan Silbert, M.B., B.S., Mohandas Jayarajah, M.B., B.S.,
Thomas Painter, M.B., Ch.B., D. James Cooper, M.D., Silvana Marasco, Ph.D.,
John McNeil, Ph.D., Jean S. Bussi res, M.D., Shay McGuinness, M.B., Ch.B.,
Kelly Byrne, M.B., Ch.B., Matthew T.V. Chan, M.B., B.S., Ph.D.,
Giovanni Landoni, M.D., and Sophie Wallace, M.P.H.,
for the ATACAS Investigators of the ANZCA Clinical Trials Network*

ABSTRACT

BACKGROUND

Tranexamic acid reduces the risk of bleeding among patients undergoing cardiac surgery, but it is unclear whether this leads to improved outcomes. Furthermore, there are concerns that tranexamic acid may have prothrombotic and proconvulsant effects.

METHODS

In a trial with a 2-by-2 factorial design, we randomly assigned patients who were scheduled to undergo coronary-artery surgery and were at risk for perioperative complications to receive aspirin or placebo and tranexamic acid or placebo. The results of the tranexamic acid comparison are reported here. The primary outcome was a composite of death and thrombotic complications (nonfatal myocardial infarction, stroke, pulmonary embolism, renal failure, or bowel infarction) within 30 days after surgery.

CRASH₂

Clinical Randomisation of an
Antifibrinolytic in Significant Haemorrhage

The logo for the CRASH2 trial. The word "CRASH" is in a bold, black, sans-serif font. The "2" is a large, black, stylized subscript. A red, glossy, 3D-rendered blood splatter graphic starts from the right side of the "H", flows under the "2", and ends in a single drop on the right. Below the main title, the text "Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage" is written in a smaller, red, sans-serif font.

TXA reduces death from bleeding in trauma



Death due to bleeding in trauma

TXA

(n= 10,060)

489 (5%)


Placebo

(n= 10,067)

574 (6%)

RR (95% CI)

0.85 (0.76–0.96) 2P=0.0077



0.8

0.9

1.0


1.1

TXA better

TXA worse

Early treatment is essential

RR (95% CI) Heterogeneity $p=0.000008$




TXA within 3 hours of injury fatal or non fatal occlusive events

Thrombotic events [#]	TXA [n = 6784]	Placebo [n = 6700]	RR (95% CI)	p-value
Any event	98 (1·4%)	141 (2·1%)	0·69 (0·53 – 0·89)	0·004
Any arterial event	47 (0·7%)	81 (1·2%)	0·57 (0·40– 0·82)	0·002
<i>Myocardial infarction</i>	23 (0·3%)	47 (0·7%)	0·48 (0·29 – 0·79)	0·003
<i>Stroke</i>	28 (0·4%)	40 (0·6%)	0·69 (0·42 – 1·12)	0·131
Any venous event	60 (0·9%)	71 (1·1%)	0·83 (0·59– 1·17)	0·299
<i>Pulmonary embolism</i>	42 (0·6%)	47 (0·7%)	0·88 (0·58 – 1·34)	0·555
<i>Deep vein thrombosis</i>	25 (0·4%)	28 (0·4%)	0·88 (0·51 – 1·51)	0·647



WOMAN Trial Collaborators

Death due to bleeding






Effect of treatment delay on the effectiveness and safety of antifibrinolytics in acute severe haemorrhage: a meta-analysis of individual patient-level data from 40 138 bleeding patients



Interpretation Death from bleeding occurs soon after onset and even a short delay in treatment reduces the benefit of tranexamic acid administration. Patients must be treated immediately. Further research is needed to deepen our understanding of the mechanism of action of tranexamic acid.



Early treatment is essential



Effect of treatment delay on the survival benefit from tranexamic acid



YEAR 2016

Median time to TXA treatment = 1.45 hours (0.85 – 2.50)

30% trauma patients received TXA within the first hour



median 49 minutes (33 – 72)



median 111 minutes (77 – 162)



Department
of Health

From the Lord O'Shaughnessy
Parliamentary Under Secretary of State for Health (Lords)

Our ref: POC-1134979

Barry Sheerman MP
House of Commons,
London,
SW1A 0AA

39 Victoria Street,
London,
SW1H 0EU

Tel: 020 7210 4850

21 JUN 2018


Dear Barry

Thank you for your letter dated 31 May 2018 regarding the usages of tranexamic acid (TXA) by paramedics.

As you correctly state, TXA has proven benefits demonstrated by research funded by the National Institute for Health Research. All ten NHS ambulance trusts now carry TXA, with clinical guidance provided by the Joint Royal College Ambulance Liaison Committee, and local guidelines and protocols in place for ambulances and acute hospital trusts.

You also mention the Best Practice Tariff (BPT) for trauma in your letter. I can confirm that in alignment with recent research findings, NHS Improvement is currently engaging on proposals to change the Major Trauma Care BPT guidance in the next tariff to cover administration of tranexamic acid within one hour of injury for patients receiving blood products. The Department of Health and Social Care continues to ensure that practice in the NHS is informed by research evidence.

I hope this reply is helpful.



JAMES O'SHAUGHNESSY


Best practice tariff for trauma:

Incentive payment if "TXA given within 3 hours if patient receives blood within 6 hours.

in alignment with recent research..



"TXA within one hour for patients receiving blood products."

TXA: Same benefit regardless of baseline risk



Most trauma patients have a low baseline risk

We need to treat all trauma patients



Tranexamic acid

Safely prevents bleeding

Give it early to all patients at risk

Not about massive transfusion

Not about trauma induced coagulopathy